NCT03196531View on ClinicalTrials.gov

A Study to Assess the Bioequivalence of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared With Clarityne Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

November 7, 2017

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Healthy
Interventions
DRUG

Loratadine (Xisimin [Test Treatment])

Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.

DRUG

Loratadine (Clarityne [Reference Treatment])

Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.

Trial Locations (1)

410008

Xiangya Hospital Central South University, Changsha

All Listed Sponsors
lead

Xian-Janssen Pharmaceutical Ltd.

INDUSTRY

NCT03196531 - A Study to Assess the Bioequivalence of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared With Clarityne Tablets | Biotech Hunter | Biotech Hunter